Skip to main content

Erratum to: TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets

The Original Article was published on 05 February 2015

ERRATUM TO: Neurotherapeutics

DOI 10.1007/s13311-015-0338-x

This article published with citation errors. Reference citations are corrected below:

TDP-43 and TDP-43 Proteinopathy, Paragraph 1: “In the nucleus, TDP-43 plays a critical role in regulating RNA splicing, as well as modulating microRNA biogenesis [8, 9].”

Reference 9 should be: Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A. 2012;109(9):3347-52. doi:10.1073/pnas.1112427109.

TDP-43 and TDP-43 Proteinopathy, Paragraph 1: “In addition to TDP-43 RNA, TDP-43 regulates the splicing and stability of a large number of other transcripts [10, 12–15], and thus influences diverse cellular processes.”

Reference 13 should be: Strong MJ, Volkening K, Hammond R, Yang W, Strong W, Leystra-Lantz C et al. TDP-43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35(2):320-327.

Reference 14 should be: Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20(7):1774-84.

TDP-43 and TDP-43 Proteinopathy, Paragraph 2: “Although mostly nuclear, up to ~30 % of TDP-43 protein can be found in the cytoplasm [16], with nuclear efflux regulated by both activity and stress [17].”

Reference 17 should be: Wang IF, Wu LS, Chang HY, Shen CK. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008;105(3):797-806. doi:10.1111/j.1471-4159.2007.05190.x.

Protein degradation gene mutations, Paragraph 1: “TDP-43 proteostasis is normally maintained by the coordinated action of the UPS and autophagy, which is particularly important for clearing TDP-43 oligomers and aggregates [81–87].”

This should be references 83-87

Protein degradation gene mutations, Paragraph 2: “Notably, VCP and p62 are required for the formation of “aggresomes” [84, 88, 89], which are large perinuclear inclusions decorated with ubiquitin, ubiquilin, and p 62.”

Reference 84 should be: Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282(33):24131-45 (originally designated reference 79)

Protein degradation gene mutations, Paragraph 2: “The TDP- 43-positive aggregates that are the hallmark ALS pathology are likely aggresomes [76, 90].”

Reference 76 should be: Scotter EL, Vance C, Nishimura AL, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci 2014;127: 1263–1278. (originally designated reference 83)

Protein degradation gene mutations, Paragraph 4: “Certainly, small molecule activators of the UPS or autophagy have been shown to promote TDP-43 clearance and/or mitigate toxicity in models based on TDP-43 overexpression [66, 77, 98, 99].”

Reference 77 should be: Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem. 2009;284(40):27416-24. (originally designated reference 84)

Environmental stress, Paragraph 1: “This idea was first proposed following observations of unexpectedly high disease incidence rates in certain “hotspots”, such as the Kii peninsula of Japan and the island of Guam [36, 123, 124].”

Reference 36 should be: Brody JA, Stanhope JM, Kurland LT. Patterns of Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia on Guam. Contemporary neurology series. 1975;12:45-70.

Reference 124 should be: Waring SC, Esteban-Santillan C, Reed DM, Craig UK, Labarthe DR, Petersen RC et al. Incidence of amyotrophic lateral sclerosis and of the parkinsonism-dementia complex of Guam, 1950-1989. Neuroepidemiology. 2004;23(4):192-200. doi:10.1159/000078505.

Environmental stress, Paragraph 1: “While patients in these regions show an increased frequency of ALS-linked genes or genetic modifiers such as MAPT [125–128], these only partly account for the observed rates of disease.”

Reference 126 should be: Poorkaj P, Tsuang D, Wijsman E, Steinbart E, Garruto RM, Craig UK et al. TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of Guam. Arch Neurol. 2001;58(11):1871-8.

Reference 127 should be: Sundar PD, Yu CE, Sieh W, Steinbart E, Garruto RM, Oyanagi K et al. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum Mol Genet. 2007;16(3):295-306. doi:10.1093/hmg/ddl463.

Environmental stress, Paragraph 1: “Proposed environmental agents underlying the high incidence in these populations include dietary neurotoxins such as β- methylamino-L-alanine [129, 130], or mineral deficiencies [75].”

Reference 129 should be: Spencer PS, Nunn PB, Hugon J, Ludolph A, Roy DN. Motorneurone disease on Guam: possible role of a food neurotoxin. Lancet. 1986;1(8487):965.

Reference 130 should be: Kisby GE, Ellison M, Spencer PS. Content of the neurotoxins cycasin (methylazoxymethanol beta-D-glucoside) and BMAA (beta-N-methylamino-L-alanine) in cycad flour prepared by Guam Chamorros. Neurology. 1992;42(7):1336-40.

Reference 75 should be: Garruto RM, Swyt C, Fiori CE, Yanagihara R, Gajdusek DC. Intraneuronal deposition of calcium and aluminium in amyotropic lateral sclerosis of Guam. Lancet. 1985;2(8468):1353.

Environmental stress, Paragraph 2: “Exposure to electromagnetic fields [87, 114],….”

Reference 87 should be: Hakansson N, Gustavsson P, Johansen C, Floderus B. Neurodegenerative diseases in welders and other workers exposed to high levels of magnetic fields. Epidemiology. 2003;14(4):420-6; discussion 7-8. doi:10.1097/01.EDE.0000078446.76859.c9.

Reference 114 should be: Li CY, Sung FC. Association between occupational exposure to power frequency electromagnetic fields and amyotrophic lateral sclerosis: a review. American journal of industrial medicine. 2003;43(2):212-20. doi:10.1002/ajim.10148.

Environmental stress, Paragraph 2: “…..agricultural chemicals [114, 115, 132]….”

Reference 114 should be: Doi H, Kikuchi H, Murai H, Kawano Y, Shigeto H, Ohyagi Y et al. Motor neuron disorder simulating ALS induced by chronic inhalation of pyrethroid insecticides. Neurology. 2006;67(10):1894-5. doi:10.1212/01.wnl.0000244489.65670.9f.

Reference 115 should be: Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler. 2006;7(3):173-82. doi:10.1080/14660820600640596.

Reference 132 should be: Furby A, Beauvais K, Kolev I, Rivain JG, Sebille V. Rural environment and risk factors of amyotrophic lateral sclerosis: a case-control study. J Neurol. 2010;257(5):792-8. doi:10.1007/s00415-009-5419-5.

Environmental stress, Paragraph 2: “…head injuries [113, 117],..”

Reference 113 should be: Chen H, Richard M, Sandler DP, Umbach DM, Kamel F. Head injury and amyotrophic lateral sclerosis. Am J Epidemiol. 2007;166(7):810-6. doi:10.1093/aje/kwm153.

Reference 117 should be: Schmidt S, Kwee LC, Allen KD, Oddone EZ. Association of ALS with head injury, cigarette smoking and APOE genotypes. J Neurol Sci. 2010;291(1-2):22-9. doi:10.1016/j.jns.2010.01.011.

Environmental stress, Paragraph 2: “…and smoking [116, 119] may also increase susceptibility.”

Reference 116 should be: Kamel F, Umbach DM, Munsat TL, Shefner JM, Sandler DP. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology. 1999;18(4):194-202. doi:26211.

Reference 119 should be: Weisskopf MG, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol. 2004;160(1):26-33. doi:10.1093/aje/kwh179.

Environmental stress, Paragraph 2: “Increased incidence of ALS has been reported in professional football players [120, 133, 134];…”

Reference 120 should be: Chio A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005;128(Pt 3):472-6. doi:10.1093/brain/awh373.

Reference 134 should be: Abel EL. Football increases the risk for Lou Gehrig's disease, amyotrophic lateral sclerosis. Perceptual and motor skills. 2007;104(3 Pt 2):1251-4. doi:10.2466/pms.104.4.1251-1254.

Environmental stress, Paragraph 2: “however, this link has been disputed [135], and risk is not increased for other professional athletes [133].”

Reference 135 should be: Valenti M, Pontieri FE, Conti F, Altobelli E, Manzoni T, Frati L. Amyotrophic lateral sclerosis and sports: a case-control study. Eur J Neurol. 2005;12(3):223-5. doi:10.1111/j.1468-1331.2004.00978.x.

Environmental stress, Paragraph 3: “Osmotic stress [136], oxidative stress [20, 137, 138], endoplasmic reticulum stress [66], and heat stress [138] can induce TDP-43 to redistribute from the nucleus to the cytoplasm and incorporate into stress granules.”

Reference 66 should be: Walker AK, Soo KY, Sundaramoorthy V, Parakh S, Ma Y, Farg MA et al. ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS One. 2013;8(11):e81170. doi:10.1371/journal.pone.0081170.

Environmental stress, Paragraph 3: “While the regulated aggregation of RBPs and RNA into stress granules is wholly reversible under normal conditions [99, 139].”

Reference 99 should be: Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N et al. Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol. 2000;151(6):1257-68.

Fragmentation of TDP-43, Paragraph 1: “CTFs that correspond in size to those in ALS patient tissue may “seed” the formation of inclusions that are detergent-resistant and ubiquitinated [80].”

Reference 80 should be: Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106(18):7607-12. (originally designated reference 87).

Misfolding, Aggregation, and Insolubility of TDP-43, Paragraph 1: “…and preventing visible TDP-43 aggregates from forming failed to reduce toxicity in a cellular model [159].”

Reference 159 should be: Liu R, Yang G, Nonaka T, Arai T, Jia W, Cynader MS. Reducing TDP-43 aggregation does not prevent its cytotoxicity. Acta neuropathologica communications. 2013;1(1):49. doi:10.1186/2051-5960-1-49.

Misfolding, Aggregation, and Insolubility of TDP-43, Paragraph 1: “It should be noted, however, that visible aggregates are only the endpoint of an aggregation pathway that includes a range of TDP-43 species from misfolded monomer to oligomer to mature aggregate [76].”

Reference 76 should be: Scotter EL, Vance C, Nishimura AL, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci 2014;127: 1263–1278. (originally designated reference 83).

Misfolding, Aggregation, and Insolubility of TDP-43, Paragraph 2: “Subsequent to misfolding, the formation of oligomers and aggregates of TDP-43 in the cytoplasm may recruit native TDP-43 or its interactors [160].”

Reference 160 should be: Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem. 2011;286(2):1204-15. doi:10.1074/jbc.M110.190884.

Misfolding, Aggregation, and Insolubility of TDP-43, Paragraph 3: “The chaperone system maintains proper protein folding during synthesis and thereafter, or delivers misfolded substrates for degradation [161].”

Reference 161 should be: Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475(7356):324-32. doi:10.1038/nature10317.

Misfolding, Aggregation, and Insolubility of TDP-43, Paragraph 3: “Monomeric misfolded TDP-43 is likely handled by the UPS [76].”

Reference 76 should be: Scotter EL, Vance C, Nishimura AL, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci 2014;127: 1263–1278. (originally designated reference 83).

Phosphorylation and Ubiquitination of TDP-43, Paragraph 3: “TDP-43 is modified with polyubiquitin chains that are predominantly K48- or K63-linked [7, 76, 173].”

Reference 76 should be: Scotter EL, Vance C, Nishimura AL, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci 2014;127: 1263–1278. (originally designated reference 83).

The following references cited originally should be disregarded:

126. Smith Bradley N, Ticozzi N, Fallini C, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 2014;84:324–331.

127. Smith BN, Vance C, Scotter EL, et al. Novel mutations support a role for Profilin1 in the pathogenesis of ALS. Neurobiol Aging 2014 Oct 31 [Epub ahead of print].

129. Jansson D, Rustenhoven J, Feng S, et al. A role for human brain pericytes in neuroinflammation. J Neuroinflammation 2014;11:104.

130. Synofzik M, Born C, Rominger A, et al. Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease. Neurobiol Aging 2014;35:1212 e1–5.

132. Mizielinska S, Lashley T, Norona FE, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 2013;126:845–857.

135. Polling S, Mok YF, Ramdzan YM, et al. Misfolded polyglutamine, polyalanine, and superoxide dismutase 1 aggregate via distinct pathways in the cell. J Biol Chem 2014;289:6669–6680.

160. Tsuiji H, Iguchi Y, Furuya A, et al. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med 2013;5:221–234.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christopher E. Shaw.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Scotter, E.L., Chen, HJ. & Shaw, C.E. Erratum to: TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics 12, 515–518 (2015). https://doi.org/10.1007/s13311-015-0351-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13311-015-0351-0